Skip to content

About
Mission

Guiding Principles

Collaborations & Partnerships

Solid Team

Management

Board of Directors

Duchenne Scientific Advisory Board

Founders

Working at Solid

Culture

Benefits

Open Positions
Our Science
Pipeline & Programs

Pipeline

Scientific Publications & Presentations

Infrastructure

Manufacturing
Patient & Caregiver Resources
Duchenne Muscular Dystrophy

What is Duchenne?

Why Gene Transfer?

Duchenne Patient Stories

Friedreich’s Ataxia Resources

Friedreich’s Ataxia

What is Frataxin?

For Patients

Strength in Community

Engaging the Community

Charity Partners

Insights & News

Resources & Policies

Expanded Access Policy

Clinical Trials
Investors & Media
Overview & News

Overview

Press Releases

Presentations

Events

Governance & Financials

Governance Documents

Committee Charters

Committee Composition

SEC Filings

Stock Information

Stock Quote Chart

Historical Price Lookup

Analyst Coverage

Investor Resources

Investor FAQs

Contact Solid Biosciences

Email Alerts

PATIENT & CAREGIVER RESOURCES

Insights & News

Letter to the Duchenne Community – INSPIRE DUCHENNE update & expansion

November 6, 2024

Letter to the Duchenne Community – INSPIRE DUCHENNE update

August 13, 2024

Letter to the Duchenne Community

November 14, 2023

Clinical Leader Article: New Advancement Toward the First Primary Endpoint Qualification of a Digital Endpoint for Duchenne

April 27, 2023

Cell & Gene Article: Project Orbis For Cell & Gene Therapies Gathers Momentum

April 25, 2023

Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and Business Update

March 23, 2023

Open letter to the Duchenne Community

December 5, 2022

Letter to the Duchenne Community: Strategic Update

September 30, 2022

Letter to the Duchenne Community: Organizational Update to Advance Development of Duchenne Gene Therapy Pipeline Programs

April 27, 2022

Letter to the Duchenne Community: Data and IGNITE DMD Phase I/II Clinical Trial Update

March 14, 2022

Biotech 2050 Podcast: Episode 87 – Dr. Joel Schneider on Solid’s Patient-Centric Approach to Gene Therapy in Duchenne

February 1, 2022

Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and 2022 Priorities

January 13, 2022

Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and Pipeline Update

November 3, 2021

Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and R&D Pipeline Development Update

August 16, 2021

Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and Pipeline Update

May 14, 2021

Letter to the Duchenne Community: Data and IGNITE DMD Clinical Trial Update

March 15, 2021

Letter to the Duchenne Community: FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial

October 1, 2020

Letter to the Duchenne Community: Update on SGT-001 Phase I/II Clinical Hold for IGNITE DMD Program

May 7, 2020

Letter to the Duchenne Community: COVID-19 Update

March 27, 2020

Letter to the Duchenne Community: Data and IGNITE DMD Clinical Trial Update

March 12, 2020

Letter to the Duchenne Community: Organizational Changes

January 9, 2020

Following is the jquery code that sets the body class to the page without a photo hero

Stay Connected

Linkedin X-twitter

Join our team of experts to advance treatments for patients

Contact Us
Privacy Policy
Terms & Conditions

Contact Us
Privacy Policy
Terms & Conditions

© 2024 Solid Biosciences Inc. All Rights Reserved.

Solid Biosciences Inc., is a Charlestown, MA based life science company focused on advancing a portfolio of neuromuscular and cardiac programs.

The characterization of the discovery and development efforts on this website, as well as the expectations associated with them, are reflective of the current state of development and may change as the Company progresses.